Kristina Oresic Bender

Kristina Oresic Bender has a long and varied work experience. Kristina began their career in 2000 as a Medical Relations Manager for L'Oréal. In 2003, they moved to the Icahn School of Medicine at Mount Sinai as a Research Coordinator, where they investigated Human cytomegalovirus (HCMV) US2 and US11. In 2009, they became a Research Scientist and Grant Office Coordinator at MedILS, where they established a biochemistry laboratory and co-authored capital equipment grants. In 2011, they became a Postdoctoral Research Fellow at Stanford University School of Medicine, where they investigated complex molecular and cellular biology concepts and published papers. In 2014, they joined Virobay Inc. as a Biomarker Lead, where they developed a biomarker program for a cathepsin S inhibitor. In 2015, they joined Achaogen as a Scientist and Project Team Leader for the Therapeutic Antibodies Program, where they led a cross-functional team on antibody discovery and validation efforts. Finally, in 2018, they joined Adverum Biotechnologies, Inc. as a Director of Clinical Development/Translational Medicine, where they were responsible for translating nonclinical and phase I clinical science data and providing strategic direction for the translational research group. Most recently, in 2022, they joined Scribe Therapeutics as their Vice President of Translational Sciences.

Kristina Oresic Bender completed a Bachelor of Science (B.Sc.) in Molecular Biology from the University of Zagreb/Sveuciliste u Zagrebu in 2004. In 2008, they received a Ph.D. in Biomedicine, Major in Biochemistry and Molecular Biology (Molecular Virology) from the University of Ljubljana. From 2012 to 2015, they were a Postdoctoral Fellow at Stanford University's School of Medicine. More recently, in 2016 and 2017, they earned an Advanced Project Management Certificate from Stanford Continuing Studies, with a focus on Executing Complex Projects and Leading Effective Teams.